Glucocorticoid-sparing maintenance of disease control in patients with systemic lupus erythematosus: 48-week results from a phase 3 trial of dapirolizumab pegol

Important Information Related to Your Request:

Dapirolizumab is an investigational product in clinical development. The safety and efficacy have not been established and it is not approved by the Food and Drug Administration, or by any health authority worldwide. The material below is provided in response to your specific search for information on UCBCOMPASS®. It is not intended to draw any conclusion regarding the efficacy and safety of dapirolizumab for any indication, dosage, or other claim.